Radiology’s technology advances threaten to push the specialty back into the dark – here is what providers need to pay attention to.
Radiology is largely the hub of all clinical activity with providers giving referring physicians the diagnostic details that are critical to patient treatment and management. But, the specialty is in danger of fading into the shadows if it is not careful.
In an editorial published in European Radiology, Adrian P. Brady, MB, head of radiology at Mercy University Hospital in Cook, Ireland, raised six red flags. There is potential, he said, for recent, useful advances that have increased radiologist productivity to actually work against the profession, pushing it to the fringes of healthcare.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
“We have spent many decades striving to bring radiology to the center of patient care. That is not going to change any time soon, but what could change is the perception of the contribution of radiologists,” he said. “We cannot expect recognition for our contribution if we hide from view. By being aware of the risks and dangers of invisibility, we can mitigate them, and continue to represent our specialty positively, and in plain sight.”
These are the areas he suggested radiologists keep top-of-mind:
Paying attention to these issues is vital, Brady said, because the work of radiology will continue. Providers must safeguard themselves from becoming strangers to the referring providers with whom they once worked face-to-face.
“If we are hidden away in an office, rarely meeting patients or referrers, it is only a small step to being forgotten,” he warned. “So, however much our technology, work circumstances, and inclinations may conspire, let us not allow ourselves become the recluses of medicine.”
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.